The Stimulator Of Interferon Genes Protein pipeline drugs market research report outlays comprehensive information on the Stimulator Of Interferon Genes Protein targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Stimulator Of Interferon Genes Protein pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, Infectious Disease, and Central Nervous System which include the indications Solid Tumor, Unspecified Cancer, Autoimmune Disorders, Inflammation, Coronavirus Disease 2019 (COVID-19), Infectious Disease, Neuroinflammation, and Parkinson’s Disease. It also reviews key players involved in Stimulator Of Interferon Genes Protein targeted therapeutics development with respective active and dormant or discontinued products.
The Stimulator Of Interferon Genes Protein pipeline targets constitutes close to 89 molecules. Out of which, approximately 80 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 6, 15, 1, 36, and 22 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 8, and 1 molecule.
Stimulator Of Interferon Genes Protein overview
Stimulator of interferon genes (STING) is a crucial protein that plays a pivotal role in the innate immune system’s defense against intracellular pathogens, including viruses, bacteria, and parasites. When intracellular DNA or cyclic dinucleotides (CDNs) produced by pathogens are detected, STING triggers a signaling cascade that leads to the production of type I interferons (IFNs).
For a complete picture of Stimulator Of Interferon Genes Protein’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
